ZYMENEX

Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. Zymenex is developing several human recombinant enzymes that can be used for therapy within specific disease areas. The products are expected to be able to help patients, who today have serious handicaps, reduced quality of life and a markedly reduced life expectancy. Enzyme replacement therapy ... is a well-known treatment method and there are a number of products on the market today that validates the company concept. The company’s Research and Development focuses on Lysosomal Storage Diseases, which is a common name for human diseases, where the ability of the human body to break down specific molecules in the lysosomes in the cells is reduced or impaired. The diseases most often affect children, they are lethal and there is no therapy available today.
ZYMENEX
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
1998-01-01
Address:
Hillerød, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.zymenex.com
Total Employee:
11+
Status:
Closed
Contact:
45 48 25 00 54
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Akari Therapeutics
Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.
Disulfican
Disulfican aims to assemble an international research collaboration focused upon the development of the drug formulation.
Keros Therapeutics
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.
Med BioGene
Med BioGene Inc. is a life science company focused on the development and commercialization of genomic-based clinical lab.
Mirnext
Mirnext focuses on the discovery, validation, and commercialization of miRNAs as novel biomarkers for cardiovascular disease.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
RiboGene
RiboGene is a drug discovery company focused on the identification of novel leads and the development of potential drug.
Current Advisors List
Board_member
2010-01-01
Current Employees Featured
Jens Fogh President @ Zymenex
President
More informations about "Zymenex"
Zymenex - Crunchbase Company Profile & Funding
Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies …See details»
Zymenex Company Profile 2024: Valuation, Investors, Acquisition
Zymenex was founded in 1998. Who is the founder of Zymenex? Jens Fogh and Pär Gellerfors are the founders of Zymenex. Where is Zymenex headquartered? Zymenex is headquartered …See details»
Zymenex - LinkedIn
Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies for the treatment of life-threatening, …See details»
Chiesi Pharma
Stockholm, Sweden June 1, 2018 – Chiesi Group, (Chiesi), an international research-focused healthcare company, today announced that it is integrating Zymenex, a highly specialized biologics company engaged in the …See details»
Zymenex - Products, Competitors, Financials, Employees, …
Zymenex, formerly Heme Biotech, is a a Danish biopharmaceutical company, founded in 1998, with headquarters in Hilleroed north of Copenhagen, Denmark and research laboratories in …See details»
Zymenex - VentureRadar
Zymenex is engaged in the research and development of safe and effective pharmaceutical products for rare genetic diseases. ... Find out more about Zymenex, Life Sciences - Biotech, …See details»
Zymenex A/S - Drug pipelines, Patents, Clinical trials - Synapse
Zymenex is a biopharmaceutical company based in Scandinavia that specializes in creating innovative enzyme replacement therapies for the treatment of severe, inherited diseases. ...See details»
Zymenex A/S - Company Profile and News - Bloomberg Markets
Company profile page for Zymenex A/S including stock price, company news, executives, board members, and contact informationSee details»
Zymenex - Crunchbase
Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies. Search Crunchbase. Start Free …See details»
Zymenex Company Profile | Management and Employees List
Find contact information for Zymenex. Learn about their Business Services, Research & Development market share, competitors, and Zymenex's email format.See details»
Zymenex - Overview, News & Similar companies | ZoomInfo.com
Zymenex develops pharmaceutical products to treat rare, serious, genetic diseases, for which there is no treatment available today. Zymenex has developed several human recombinant …See details»
Zymenex - Sunstone
Zymenex In 2008, the company’s lead product, Metazym for the treatment of Metachromatic Leukodystrophy (MLD), was acquired by Shire Pharmaceuticals for USD 135 million. …See details»
Zymenex - Company Profile - Tracxn
Zymenex - Enzyme replacement therapies for the treatment of lysosomal storage diseases such as Alpha-Mannosidosis, Krabbe disease.. Raised funding from 3 investors. Zymenex has 27 …See details»
Zymenex | IT History Society
Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapiesZymenex is a Scandinavian …See details»
Sunstone Capital sells Zymenex Holding A/S - Nordic Life Science
Aug 27, 2013 Danish Zymenex is a biopharmaceutical group focused on research and development of innovative biologic therapeutics for the treatment of rare and life threatening …See details»
Zymenex - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Zymenex . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Number of Board Member and …See details»
G-0107 - Drug Targets, Indications, Patents - Synapse
G-0107: a Enzymes modulators Drug, Initially developed by Zymenex A/S, Now, its global highest R&D status is Pending, Mechanism: Enzymes modulators, Therapeutic Areas: Congenital …See details»
ZYMENEX HEALTHCARE LLP | Investors, Shareholders ... - Zauba Corp
ZYMENEX HEALTHCARE LLP As on: 2024-06-14. Zymenex Healthcare Llp is a Limited Liability Partnership firm incorporated on 18 January 2018. It is registered at Registrar of Companies, …See details»
Zymenex - Tech Stack, Apps, Patents & Trademarks - Crunchbase
The intellectual property of Zymenex includes 2 registered patents primarily in the ' Organic Chemistry ' category, according to IPqwery. Additionally, Zymenex has registered 4 …See details»
5 years after European nod, Chiesi gets FDA approval for Lamzede
Feb 17, 2023 After purchasing the enzyme replacement therapy in its 2013 acquisition of Zymenex, Chiesi scored approval for it in Europe in 2018. Now, five more years later, the …See details»